I have been working in scientific research for more than ten years. I was concerned with chronic hepatic diseases such as liver fibrosis, non-alcoholic steatohepatitis (NASH), and liver cancer. I studied the effect of metabolic disorders such as insulin resistance as predisposing factors for NASH and liver cancer. As a Doctor of Clinical Pharmacy and pharmacology, I sought novel therapeutic interventions with a safety profile. I investigated different natural product effects on liver fibrosis, insulin resistance modulation, and NASH prevention. Also, I studied the pathophysiology of fibrosis, insulin resistance, and lipid metabolism looking for new biological molecules that have a fundamental role in disease prevention. Currently, I work in GCPR signaling in adipose tissue and its role in obesity and thermogenesis as well as the ANP clearance by NPRC receptors in obesity.